Ispaghula Seed
Plantaginis ovatae semen
Plantago ovata Forssk.
HOS-215982hmpc:plantaginis-ovatae-semen
Botanische Abbildung
Photo of Plantago ovata (desert plantain) on southwestern slope of Frenchman Mountain east of Las Vegas, Nevada
Artbezogene Illustration. Sie zeigt nicht automatisch die im Profil genannte Arzneidroge oder Zubereitung und dient nicht zur sicheren Bestimmung einer Giftpflanze.
Stan Shebs · CC BY-SA 3.0 · Bildquelle ↗
Bildzuordnung & Herkunft
- Originalangabe im Profil
- Plantago ovata Forssk.
- Taxonkennung
- Q311228 · Quellenrevision 2536498843
- Bearbeitung
- Auf maximal 1024 Pixel verkleinert, EXIF-Orientierung angewandt und als JPEG gespeichert; kein inhaltlicher Zuschnitt.
- Bildquelle abgerufen
- 25.10.2026
Bilddatei SHA-256: 7da0a9e1f674fcc985808d39605b0eac14e4e7b5a4d14df51f673dbeeb268b74
- Themengebiete laut EMA
- Constipation
- Ergebnis der Bewertung laut EMA
- European Union herbal monograph
- Kombination laut EMA
- Nein
Pflanzen–Arzneimittel-Beziehungen 2 belegte Zuordnungen
Warnungen, berichtete Effekte und verneinte Studienbefunde werden getrennt ausgewiesen und mit eindeutig bezeichneten Wirkstoffen verknüpft. Jede Aussage gilt im Zubereitungs- und Anwendungskontext der Quelle. Ein klinischer Schweregrad wird daraus nicht abgeleitet.
carbamazepine
Berichteter EffektEtablierte Anwendung · Quellenspalte · Keine wirkstoffbezogene Einschränkung abgeleitet · Schweregrad: nicht angegeben
Die Quelle beschreibt einen möglichen oder beobachteten Effekt; auch ein Verdachtsfall ist damit möglich. Allgemeine Warnungen und weitere Bedingungen bleiben im Originalzitat erhalten. Daraus wurde hier keine zusätzliche Einschränkung für den einzelnen Wirkstoff abgeleitet.
HOS-215982HOS-085618RxNorm 2002
Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed. For this reason the product should not be taken ½ to 1 hour before or after intake of other medicinal products.
Zubereitungskontext & Beleg
Wortlaut der zugeordneten Aussage:
Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed.
1. Name of the medicinal product To be specified for the individual finished product. 2. Qualitative and quantitative composition 1,2 Well-established use Traditional use With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC as amended Plantago ovata Forssk. (P. ispaghula Roxb.), semen (ispaghula seed) i) Herbal substance Dried ripe seeds ii) Herbal preparations Powdered herbal substance 3. Pharmaceutical form Well-established use Traditional use Herbal substance for oral use; herbal preparation in solid dosage forms for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term. 4. Clinical particulars 4.1. Therapeutic indications Well-established use Traditional use Indication 1) Herbal medicinal product for the treatment of habitual constipation. Indication 2) Herbal medicinal product in conditions in which easy defecation with soft stool is desirable, e.g. in cases of painful defecation after rectal or anal 1 The material complies with the Eur. Ph. monograph monograph (ref.: 01/2008:1333). 2 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. Community herbal monograph on Plantago ovata Forssk., semen EMA/HMPC/304390/2012 Page 4/10 Well-established use Traditional use surgery, anal fissures and haemorrhoids. 4.2. Posology and method of administration Well-established use Traditional use Posology Adolescents, adults and elderly Daily dose 8 - 40 g herbal substance/herbal preparation in 2 - 3 single doses Children from 6 to 12 years of age Daily dose 4 - 25 g herbal substance/herbal preparation in 2 – 3 single doses. The use in children under 6 years of age is not recommended (see section 4.4 ‘Special warnings and precautions for use’). Duration of use If the constipation does not resolve within 3 days, a doctor or a pharmacist should be consulted. See section 4.4 ‘Special warnings and precautions for use’. Method of administration A sufficient amount of liquid (water, milk, fruit juice or similar aqueous liquid) should always be taken e.g. 30 ml of water per 1 g of herbal substance. The medicinal product can be mixed with the liquids and then swallowed or taken and then swallowed with sufficient quantity of liquid. Adequate fluid intake has to be maintained. The product should be taken during the day at least ½ to 1 hour before or after intake of other medicines, not immediately prior to bed-time. The effect starts 12 - 24 hours later. Powder formulations: When preparing the product for administration, it is important to try to avoid inhaling any of the powder in order to minimise the risk of sensitisation to the active ingredient. Community herbal monograph on Plantago ovata Forssk., semen EMA/HMPC/304390/2012 Page 5/10 4.5. Interactions with other medicinal products and other forms of interaction Well-established use Traditional use Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed. For this reason the product should not be taken ½ to 1 hour before or after intake of other medicinal products. Diabetic patients should take ispaghula seeds only under medical supervision because adjustment of anti-diabetic therapy may be necessary. Use of ispaghula seed concomitantly with thyroid hormones requires medical supervision because the dose of the thyroid hormones may have to be adjusted. Community herbal monograph on Plantago ovata Forssk., semen EMA/HMPC/304390/2012 Page 7/10PDF SHA-256:
39a176bd67181a7662349d120e50bd9eaa879dda95a76a89f22cce24c86a4969Die Zuordnung verbindet dieses HMPC-Quellenprofil mit dem genannten Wirkstoff. Sie ist keine Aussage über jedes Präparat aus dieser Pflanzenart.
lithium
Berichteter EffektEtablierte Anwendung · Quellenspalte · Keine wirkstoffbezogene Einschränkung abgeleitet · Schweregrad: nicht angegeben
Die Quelle beschreibt einen möglichen oder beobachteten Effekt; auch ein Verdachtsfall ist damit möglich. Allgemeine Warnungen und weitere Bedingungen bleiben im Originalzitat erhalten. Daraus wurde hier keine zusätzliche Einschränkung für den einzelnen Wirkstoff abgeleitet.
HOS-215982HOS-085952RxNorm 6448
Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed. For this reason the product should not be taken ½ to 1 hour before or after intake of other medicinal products.
Zubereitungskontext & Beleg
Wortlaut der zugeordneten Aussage:
Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed.
1. Name of the medicinal product To be specified for the individual finished product. 2. Qualitative and quantitative composition 1,2 Well-established use Traditional use With regard to the marketing authorisation application of Article 10(a) of Directive 2001/83/EC as amended Plantago ovata Forssk. (P. ispaghula Roxb.), semen (ispaghula seed) i) Herbal substance Dried ripe seeds ii) Herbal preparations Powdered herbal substance 3. Pharmaceutical form Well-established use Traditional use Herbal substance for oral use; herbal preparation in solid dosage forms for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term. 4. Clinical particulars 4.1. Therapeutic indications Well-established use Traditional use Indication 1) Herbal medicinal product for the treatment of habitual constipation. Indication 2) Herbal medicinal product in conditions in which easy defecation with soft stool is desirable, e.g. in cases of painful defecation after rectal or anal 1 The material complies with the Eur. Ph. monograph monograph (ref.: 01/2008:1333). 2 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. Community herbal monograph on Plantago ovata Forssk., semen EMA/HMPC/304390/2012 Page 4/10 Well-established use Traditional use surgery, anal fissures and haemorrhoids. 4.2. Posology and method of administration Well-established use Traditional use Posology Adolescents, adults and elderly Daily dose 8 - 40 g herbal substance/herbal preparation in 2 - 3 single doses Children from 6 to 12 years of age Daily dose 4 - 25 g herbal substance/herbal preparation in 2 – 3 single doses. The use in children under 6 years of age is not recommended (see section 4.4 ‘Special warnings and precautions for use’). Duration of use If the constipation does not resolve within 3 days, a doctor or a pharmacist should be consulted. See section 4.4 ‘Special warnings and precautions for use’. Method of administration A sufficient amount of liquid (water, milk, fruit juice or similar aqueous liquid) should always be taken e.g. 30 ml of water per 1 g of herbal substance. The medicinal product can be mixed with the liquids and then swallowed or taken and then swallowed with sufficient quantity of liquid. Adequate fluid intake has to be maintained. The product should be taken during the day at least ½ to 1 hour before or after intake of other medicines, not immediately prior to bed-time. The effect starts 12 - 24 hours later. Powder formulations: When preparing the product for administration, it is important to try to avoid inhaling any of the powder in order to minimise the risk of sensitisation to the active ingredient. Community herbal monograph on Plantago ovata Forssk., semen EMA/HMPC/304390/2012 Page 5/10 4.5. Interactions with other medicinal products and other forms of interaction Well-established use Traditional use Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed. For this reason the product should not be taken ½ to 1 hour before or after intake of other medicinal products. Diabetic patients should take ispaghula seeds only under medical supervision because adjustment of anti-diabetic therapy may be necessary. Use of ispaghula seed concomitantly with thyroid hormones requires medical supervision because the dose of the thyroid hormones may have to be adjusted. Community herbal monograph on Plantago ovata Forssk., semen EMA/HMPC/304390/2012 Page 7/10PDF SHA-256:
39a176bd67181a7662349d120e50bd9eaa879dda95a76a89f22cce24c86a4969Die Zuordnung verbindet dieses HMPC-Quellenprofil mit dem genannten Wirkstoff. Sie ist keine Aussage über jedes Präparat aus dieser Pflanzenart.
Keine oder wenige Zuordnungen bedeuten nicht, dass keine Wechselwirkungen bestehen. Nicht eindeutig zuordenbare Aussagen bleiben im Originalabschnitt nachlesbar; verneinte Befunde gelten nur für die beschriebenen Bedingungen.
Sicherheit aus der Monographie Originalabschnitte
Englische Originalabschnitte mit unveränderten Spalten für etablierte und traditionelle Anwendung. Aussagen gelten für die im Dokument genannten Zubereitungen und Anwendungsarten. Aus ihnen werden hier keine Interaktionspaare oder Schweregrade abgeleitet.
Final Community herbal monograph on Plantago ovata Forssk., semen ↗
PDF abgerufen: 27.10.2026 · 10 Seiten · automatisch ausgelesen
Zubereitungs- und Anwendungskontext · Originaltext
Originalkontext vor Abschnitt 4.3, einschließlich der Angaben zu Zubereitungen und Anwendung. Buchstaben und Nummern der Zubereitungen werden in den Sicherheitsabschnitten wieder aufgegriffen.
1. Name of the medicinal product
To be specified for the individual finished product.
2. Qualitative and quantitative composition 1,2
Well-established use Traditional use
With regard to the marketing authorisation
application of Article 10(a) of Directive
2001/83/EC as amended
Plantago ovata Forssk. (P. ispaghula Roxb.),
semen (ispaghula seed)
i) Herbal substance
Dried ripe seeds
ii) Herbal preparations
Powdered herbal substance
3. Pharmaceutical form
Well-established use Traditional use
Herbal substance for oral use; herbal preparation
in solid dosage forms for oral use.
The pharmaceutical form should be described by
the European Pharmacopoeia full standard term.
4. Clinical particulars
4.1. Therapeutic indications
Well-established use Traditional use
Indication 1)
Herbal medicinal product for the treatment of
habitual constipation.
Indication 2)
Herbal medicinal product in conditions in which
easy defecation with soft stool is desirable, e.g. in
cases of painful defecation after rectal or anal
1
The material complies with the Eur. Ph. monograph monograph (ref.: 01/2008:1333).
2
The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal
quality guidance.
Community herbal monograph on Plantago ovata Forssk., semen
EMA/HMPC/304390/2012 Page 4/10
Well-established use Traditional use
surgery, anal fissures and haemorrhoids.
4.2. Posology and method of administration
Well-established use Traditional use
Posology
Adolescents, adults and elderly
Daily dose
8 - 40 g herbal substance/herbal preparation in
2 - 3 single doses
Children from 6 to 12 years of age
Daily dose
4 - 25 g herbal substance/herbal preparation in
2 – 3 single doses.
The use in children under 6 years of age is not
recommended (see section 4.4 ‘Special warnings
and precautions for use’).
Duration of use
If the constipation does not resolve within 3 days,
a doctor or a pharmacist should be consulted.
See section 4.4 ‘Special warnings and precautions
for use’.
Method of administration
A sufficient amount of liquid (water, milk, fruit
juice or similar aqueous liquid) should always be
taken e.g. 30 ml of water per 1 g of herbal
substance.
The medicinal product can be mixed with the
liquids and then swallowed or taken and then
swallowed with sufficient quantity of liquid.
Adequate fluid intake has to be maintained.
The product should be taken during the day at
least ½ to 1 hour before or after intake of other
medicines, not immediately prior to bed-time.
The effect starts 12 - 24 hours later.
Powder formulations:
When preparing the product for administration, it
is important to try to avoid inhaling any of the
powder in order to minimise the risk of
sensitisation to the active ingredient.
Community herbal monograph on Plantago ovata Forssk., semen
EMA/HMPC/304390/2012 Page 5/10Kontext im Original-PDF öffnen ↗4.3 · Gegenanzeigen
Contraindications
4.3. Contraindications
Well-established use Traditional use
Hypersensitivity to the active substance (for
powder formulations add: See section 4.4 ‘Special
warnings and precautions for use’).
Patients with a sudden change in bowel habit that
persists for more than 2 weeks.
Undiagnosed rectal bleeding and failure to
defecate following the use of a laxative.
Patients suffering from abnormal constrictions in
the gastro-intestinal tract, with diseases of the
oesophagus and cardia, potential or existing
intestinal blockage (ileus), paralysis of the
intestine or megacolon.
Patients who have difficulty in swallowing or any
throat problems.Original-PDF · Seite 5 ↗4.4 · Warnhinweise und Vorsichtsmaßnahmen
Special warnings and precautions for use
4.4. Special warnings and precautions for use
Well-established use Traditional use
The use is not recommended in children below
6 years of age due to insufficient data on efficacy.
Laxative bulk producers should be used before
using other purgatives if change of nutrition is not
successful.
A sufficient amount of liquid should always be
taken e.g. 30 ml of water per 1 g of herbal
substance.
Ispaghula seed should not be used by patients
with faecal impaction and symptoms such as
abdominal pain, nausea and vomiting unless
advised by a doctor because these symptoms can
be signs of potential or existing intestinal blockage
(ileus).
If abdominal pain occurs or in cases of any
irregularity of faeces, the use of ispaghula seed
should be discontinued and medical advice must
be sought.
When taken with inadequate fluid amounts, bulk
forming agents can cause obstruction of the
throat and oesophagus with choking and intestinal
obstruction. Symptoms can be chest pain,
vomiting, or difficulty in swallowing or breathing.
Community herbal monograph on Plantago ovata Forssk., semen
EMA/HMPC/304390/2012 Page 6/10
Well-established use Traditional use
The treatment of debilitated patients and / or
elderly patients requires medical supervision.
In order to decrease the risk of gastrointestinal
obstruction (ileus) ispaghula seed should be used
together with medicinal products known to inhibit
peristaltic movement (e.g. opioids) only under
medical supervision.
Powder formulations:
Warning on hypersensitive reactions
In individuals with continued occupational contact
to powder of Plantago ovata seeds or husks (i.e.
healthcare workers, caregivers) allergic
sensitisation may occur due to inhalation, this is
more frequent in atopic individuals. This
sensitisation usually leads to hypersensitivity
reactions which could be serious (see 4.8
‘Undesirable effects’).
It is recommended to assess clinically the possible
sensitisation of individuals at risk and, if justified,
to perform specific diagnostic tests.
In case of proven sensitisation leading to
hypersensitivity reactions, exposure to the
product should be stopped immediately and
avoided in the future (see 4.3 ‘Contraindications’).Original-PDF · Seite 5–6 ↗4.5 · Wechselwirkungen
Interactions with other medicinal products and other forms of interaction
4.5. Interactions with other medicinal products and other forms of
interaction
Well-established use Traditional use
Enteral absorption of concomitantly administered
medicines such as minerals, vitamins (B 12),
cardiac glycosides, coumarin derivatives,
carbamazepine and lithium may be delayed. For
this reason the product should not be taken ½ to
1 hour before or after intake of other medicinal
products.
Diabetic patients should take ispaghula seeds only
under medical supervision because adjustment of
anti-diabetic therapy may be necessary.
Use of ispaghula seed concomitantly with thyroid
hormones requires medical supervision because
the dose of the thyroid hormones may have to be
adjusted.
Community herbal monograph on Plantago ovata Forssk., semen
EMA/HMPC/304390/2012 Page 7/10Original-PDF · Seite 6 ↗4.8 · Nebenwirkungen
Undesirable effects
4.8. Undesirable effects
Well-established use Traditional use
Flatulence may occur with the use of the product,
which generally disappears in the course of the
treatment. Abdominal distension and risk of
intestinal or oesophageal obstruction and faecal
impaction may occur, particularly if swallowed
with insufficient fluid. The frequency is not known.
Ispaghula contains potent allergens. The exposure
to these allergens is possible through oral
administration, contact with the skin and, in the
case of powder formulations, also by inhalation.
As a consequence to this allergic potential,
individuals exposed to the product can develop
hypersensitivity reactions such as rhinitis,
conjunctivitis, bronchospasm and in some cases,
anaphylaxis. Cutaneous symptoms such as
exanthema and/or pruritus have also been
reported. Special attention should be given to
individuals manipulating the powder formulations
routinely (see 4.4 ‘Special warnings and
precautions for use’). The frequency is not known.
If other adverse reactions not mentioned above
Community herbal monograph on Plantago ovata Forssk., semen
EMA/HMPC/304390/2012 Page 8/10
Well-established use Traditional use
occur, a doctor or a pharmacist should be
consulted.Original-PDF · Seite 7–8 ↗Dokumentfassung nachweisen
SHA-256: 39a176bd67181a7662349d120e50bd9eaa879dda95a76a89f22cce24c86a4969
Der Hash kennzeichnet die abgerufene Datei. Die Dokumentfassung und der Bearbeitungsstatus des Pflanzenprofils sind getrennte Angaben.
Importstand: 27.10.2026 · Aktuelles EMA-Quellenprofil ↗
Dokumente beim Herausgeber · 13
Originaltitel bleiben erhalten. Entwürfe, ältere Fassungen und ergänzende Berichte können nebeneinander vorliegen; der Profilstatus bestimmt nicht die Gültigkeit jedes Dokuments.
- Call for scientific data for the periodic review of the monograph on Plantaginis ovatae semen
- Call for scientific data for the systematic review of the monograph on Plantago ovata Forssk., semen
- Superseded overview of comments received on Community herbal monograph on plantago ovata Forssk., semen (EMEA/HMPC/340861/2005)
- Draft Community herbal monograph on Plantago ovata Forskk., semen
- Final Community herbal monograph on Plantago ovata Forssk., semen
- Superseded community herbal monograph on Plantago ovata Forssk., semen
- Opinion of the HMPC on a Community herbal monograph on Plantago ovata Forssk., semen
- Superseded opinion of the HMPC on a Community herbal monograph on Plantago ovata Forssk., semen
- Final list of references supporting the assessment of Plantago ovata Forssk., semen
- Superseded list of references supporting the HMPC Assessment Report on Plantago ovata Forssk., semen (EMEA/HMPC/166377/2006)
- Final assessment report on Plantago ovata Forskk., semen
- Superseded assessment report on Plantago ovata Forssk., semen
- Ispaghula seed - Summary for the public
Dokumentenlinks geprüft: 27.10.2026
Quellenstand & Originalangaben
- Originalstatus
- C: ongoing call for scientific data
- Zuletzt geändert laut EMA
- 15/02/2024
- Erstveröffentlichung laut EMA
- 31/12/2009
- Erfolgreicher Quellenabruf
- 27.10.2026